http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Apr 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html <p align="justify">ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“<strong>KALA</strong>” or the “<strong>Company</strong>”) today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research, representing the most sweeping shift in U.S. federal psychedelic policy in decades.</p> <p align="justify">The Executive Order arrives at a pivotal http://www.streetinsider.com/Press+Releases/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html Tue, 21 Apr 2026 07:00:00 -0400 4YX KALA O.00791126 O.08215638 TRIP TRUFF http://www.streetinsider.com/Press+Releases/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html <p align="justify">ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“<strong>KALA</strong>” or the “<strong>Company</strong>”) today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research, representing the most sweeping shift in U.S. federal psychedelic policy in decades.</p> <p align="justify">The Executive Order arrives at a pivotal http://www.streetinsider.com/Press+Releases/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html Tue, 21 Apr 2026 07:00:00 -0400 4YX KALA O.00791126 O.08215638 TRIP TRUFF http://www.streetinsider.com/Press+Releases/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html <p align="justify">ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“<strong>KALA</strong>” or the “<strong>Company</strong>”) today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research, representing the most sweeping shift in U.S. federal psychedelic policy in decades.</p> <p align="justify">The Executive Order arrives at a pivotal http://www.streetinsider.com/Press+Releases/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html Tue, 21 Apr 2026 07:00:00 -0400 4YX KALA O.00791126 O.08215638 TRIP TRUFF http://www.streetinsider.com/Press+Releases/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html <p align="justify">ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“<strong>KALA</strong>” or the “<strong>Company</strong>”) today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research, representing the most sweeping shift in U.S. federal psychedelic policy in decades.</p> <p align="justify">The Executive Order arrives at a pivotal http://www.streetinsider.com/Press+Releases/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html Tue, 21 Apr 2026 07:00:00 -0400 4YX KALA O.00791126 O.08215638 TRIP TRUFF http://www.streetinsider.com/Press+Releases/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html <p align="justify">ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“<strong>KALA</strong>” or the “<strong>Company</strong>”) today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research, representing the most sweeping shift in U.S. federal psychedelic policy in decades.</p> <p align="justify">The Executive Order arrives at a pivotal http://www.streetinsider.com/Press+Releases/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html Tue, 21 Apr 2026 07:00:00 -0400 4YX KALA O.00791126 O.08215638 TRIP TRUFF http://www.streetinsider.com/Press+Releases/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html <p align="justify">ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“<strong>KALA</strong>” or the “<strong>Company</strong>”) today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research, representing the most sweeping shift in U.S. federal psychedelic policy in decades.</p> <p align="justify">The Executive Order arrives at a pivotal http://www.streetinsider.com/Press+Releases/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html Tue, 21 Apr 2026 07:00:00 -0400 4YX KALA O.00791126 O.08215638 TRIP TRUFF http://www.streetinsider.com/Globe+Newswire/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html <p align="justify">ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“<strong>KALA</strong>” or the “<strong>Company</strong>”) today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research, representing the most sweeping shift in U.S. federal psychedelic policy in decades.</p> <p align="justify">The Executive Order arrives at a pivotal http://www.streetinsider.com/Globe+Newswire/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html Tue, 21 Apr 2026 07:00:00 -0400 4YX KALA O.00791126 O.08215638 TRIP TRUFF http://www.streetinsider.com/Globe+Newswire/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html <p align="justify">ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“<strong>KALA</strong>” or the “<strong>Company</strong>”) today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research, representing the most sweeping shift in U.S. federal psychedelic policy in decades.</p> <p align="justify">The Executive Order arrives at a pivotal http://www.streetinsider.com/Globe+Newswire/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html Tue, 21 Apr 2026 07:00:00 -0400 4YX KALA O.00791126 O.08215638 TRIP TRUFF http://www.streetinsider.com/Globe+Newswire/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html <p align="justify">ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“<strong>KALA</strong>” or the “<strong>Company</strong>”) today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research, representing the most sweeping shift in U.S. federal psychedelic policy in decades.</p> <p align="justify">The Executive Order arrives at a pivotal http://www.streetinsider.com/Globe+Newswire/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html Tue, 21 Apr 2026 07:00:00 -0400 4YX KALA O.00791126 O.08215638 TRIP TRUFF http://www.streetinsider.com/Globe+Newswire/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html <p align="justify">ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“<strong>KALA</strong>” or the “<strong>Company</strong>”) today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research, representing the most sweeping shift in U.S. federal psychedelic policy in decades.</p> <p align="justify">The Executive Order arrives at a pivotal http://www.streetinsider.com/Globe+Newswire/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html Tue, 21 Apr 2026 07:00:00 -0400 4YX KALA O.00791126 O.08215638 TRIP TRUFF http://www.streetinsider.com/Globe+Newswire/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html <p align="justify">ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“<strong>KALA</strong>” or the “<strong>Company</strong>”) today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research, representing the most sweeping shift in U.S. federal psychedelic policy in decades.</p> <p align="justify">The Executive Order arrives at a pivotal http://www.streetinsider.com/Globe+Newswire/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html Tue, 21 Apr 2026 07:00:00 -0400 4YX KALA O.00791126 O.08215638 TRIP TRUFF http://www.streetinsider.com/Globe+Newswire/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html <p align="justify">ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“<strong>KALA</strong>” or the “<strong>Company</strong>”) today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research, representing the most sweeping shift in U.S. federal psychedelic policy in decades.</p> <p align="justify">The Executive Order arrives at a pivotal http://www.streetinsider.com/Globe+Newswire/Kala+Bio+Celebrates+Trump+Executive+Order+as+Game-Changer+for+Psychedelic+Medicine/26339687.html Tue, 21 Apr 2026 07:00:00 -0400 4YX KALA O.00791126 O.08215638 TRIP TRUFF